Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-Inferiority Trial

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Roukens, Anna H ^a   Vossen, Ann C ^a,b   Bredenbeek, Peter J ^a   van Dissel, Jaap T ^a   Visser, Leo G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNITY; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 44349085344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001993     Document Type: Article

References (26)

1. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, et al.(1996) Yellow fever: a decade of reemergence. JAMA 276: 1157-1162.
2. Monath TP, (2001) Yellow fever: an update. Lancet Infect Dis 1: 11-20.
3. WHO(2005) Weekly epidemiological record. Yellow fever situation in Africa and South America. 81: 317-324 http://www.who.int/wer/2006/wer8133.pdf Accessed 10 Oct 2007.
4. Roberts L, (2007) Infectious disease. Resurgence of yellow fever in Africa prompts a counterattack. Science 316: 1109.
5. Monath TP, (1999) Yellow Fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. W.B. Saunders Company pp. 815-879.
6. Monath TP, (1996) Stability of yellow fever vaccine. Dev Biol Stand 87: 219-225.
7. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, et al.(2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351: 2286-2294.
8. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM, (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351: 2295-2301.
9. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH, (1985) Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254: 3203-3206.
10. Warrell MJ, Warrell DA, Suntharasamai P, Viravan C, Sinhaseni A, et al.(1983) An economical regimen of human diploid cell strain anti-rabies vaccine for post exposure prophylaxis. Lancet 2: 301-304.
11. Fox JP, Luty Kossobudski S, Fonseca da Cunha J, (1943) Field studies on the immune response to 17D yellow fever virus. Relation to virus substrain, dose and route of inoculation. The American Journal of Hygiene 38: 113-138.
12. Cannon SA, Dewhurst F, (1953) Vaccination by scarification with 17D yellow fever vaccine prepared at Yaba, Lagos, Nigeria. Ann Trop Med Parasitol 47: 381-393.
13. Dick GW, (1952) A preliminary evaluation of the immunizing power of chick-embryo 17 D yellow fever vaccine inoculated by scarification. Am J Hyg 55: 140-153.
14. Center for Disease Control, Mantoux Tuberculosis Skin Test Facilitator Guide. http://www.cdc.gov/tb/pubs/Mantoux/part1.htm (accessed 2nd of August 2007).
15. De Madrid AT, Porterfield JS, (1969) A simple micro-culture method for the study of group B arboviruses. Bulletin of the World Health Organization 40: 113-121.
16. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, (1873) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539-544.
17. Nijhuis M, van Maarseveen N, Schuurman R, Verkuijlen S, de Vos M, et al.(2002) Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol 40: 3666-3670.
18. Drosten C, Gottig S, Schilling S, Asper M, Panning M, et al.(2002) Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40: 2323-2330.
19. Armitage P, Berry G, Matthews J, (2002) Statistical methods in medical research. 4 ed Oxford Blackwell Science.
20. World Health Organization Expert Committee on Biological Standardization. 46th report(1998) WHO Technical Report ser. No. 872. Geneva, World Health Organization.
21. Monath TP, (2005) Yellow Fever Vaccine. Exp rev vaccines 4: 553-574.
22. Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, et al.(2005) Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Human Vaccin 1: 106-111.
23. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, (1998) Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159-167.
24. Barba-Spaeth G, Longman RS, Albert ML, Rice CM, (2005) Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202: 1179-1184.
25. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, et al.(2007) Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88: 148-156.
26. WHO(2007) 82: 153-160 Weekly epidemiological record. Assessment of yellow fever epidemic risk-a decision-making tool for preventive immunization campaigns. http://www.who.int/wer/2007/wer8218.pdf.